Skip to content

Study · Animal study (in vivo) · horse · 2012

5 results

Comparison of Efficacy of Two Dose Rates of Histrelin to Human Chorionic Gonadotropin for Inducing Ovulation in Broodmares

Voge JL, Kendrick Sudderth A, Brinsko SP, Burns PJ, Blanchard TL

Journal of equine veterinary science1 Apr 2012Cited by 8 (Europe PMC)

DOI10.1016/j.jevs.2011.09.065 (opens in a new tab)PepBankPUB-90323451
Publisher pageAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mares, ovulation within 2 days occurred in 34/37 (92%) with 1.0-mg BioRelease Histrelin versus 31/37 (84%) with hCG; the three-group comparison was nonsignificant (P = .45).

    In plain wordsIn mares, ovulation within 2 days did not differ significantly between 1.0-mg BioRelease Histrelin and hCG.

    Peptide
    Histrelin
    Outcome
    No significant changeOvulation within 2 days at 1.0 mg
    Study

    horsen: not reported in source

    Broodmares in estrus
    Comparator
    2,500-unit intravenous hCG
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    1.0 mg · intramuscularAs given in this study (horse).

    Source sentences

    Summary
    A nonsignificant trend for higher ovulation rates within 2 days was noted for both dose rates of histrelin compared with hCG treatment (31/37, 84%; 34/37, 92%; and 33/36, 92% for groups 1-3, respectively) (P = .45).
    1 context sentence
    Summary · context
    group (1) 2,500-unit human chorionic gonadotropin (hCG), intravenous; group (2) 1.0-mg BioRelease Histrelin (Biorelease Technologies, Lexington, KY), intramuscular; or group (3) 0.5-mg BioRelease Histrelin, intramuscular.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mares, ovulation within 2 days occurred in 33/36 (92%) with 0.5-mg BioRelease Histrelin versus 31/37 (84%) with hCG; the three-group comparison was nonsignificant (P = .45).

    In plain wordsIn mares, ovulation within 2 days did not differ significantly between 0.5-mg BioRelease Histrelin and hCG.

    Peptide
    Histrelin
    Outcome
    No significant changeOvulation within 2 days at 0.5 mg
    Study

    horsen: not reported in source

    Broodmares in estrus
    Comparator
    2,500-unit intravenous hCG
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.5 mg · intramuscularAs given in this study (horse).

    Source sentences

    Summary
    A nonsignificant trend for higher ovulation rates within 2 days was noted for both dose rates of histrelin compared with hCG treatment (31/37, 84%; 34/37, 92%; and 33/36, 92% for groups 1-3, respectively) (P = .45).
    1 context sentence
    Summary · context
    group (1) 2,500-unit human chorionic gonadotropin (hCG), intravenous; group (2) 1.0-mg BioRelease Histrelin (Biorelease Technologies, Lexington, KY), intramuscular; or group (3) 0.5-mg BioRelease Histrelin, intramuscular.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mares, monthly ovulation response rates did not differ between histrelin and hCG (P ≥ .50).

    In plain wordsIn mares, monthly ovulation responses did not differ between histrelin and hCG.

    Peptide
    Histrelin
    Outcome
    No significant changeMonthly ovulation response at 1.0 mg
    Study

    horsen: not reported in source

    Broodmares in estrus
    Comparator
    2,500-unit intravenous hCG
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    1.0 mg · intramuscularAs given in this study (horse).

    Source sentences

    Summary
    Ovulatory responses appeared to improve for both products as the season progressed, yet no differences were detected between response rates to histrelin or hCG for any month (P ≥ .50).
    1 context sentence
    Summary · context
    group (1) 2,500-unit human chorionic gonadotropin (hCG), intravenous; group (2) 1.0-mg BioRelease Histrelin (Biorelease Technologies, Lexington, KY), intramuscular; or group (3) 0.5-mg BioRelease Histrelin, intramuscular.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mares, monthly ovulation response rates did not differ between histrelin and hCG (P ≥ .50).

    In plain wordsIn mares, monthly ovulation responses did not differ between histrelin and hCG.

    Peptide
    Histrelin
    Outcome
    No significant changeMonthly ovulation response at 0.5 mg
    Study

    horsen: not reported in source

    Broodmares in estrus
    Comparator
    2,500-unit intravenous hCG
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.5 mg · intramuscularAs given in this study (horse).

    Source sentences

    Summary
    Ovulatory responses appeared to improve for both products as the season progressed, yet no differences were detected between response rates to histrelin or hCG for any month (P ≥ .50).
    1 context sentence
    Summary · context
    group (1) 2,500-unit human chorionic gonadotropin (hCG), intravenous; group (2) 1.0-mg BioRelease Histrelin (Biorelease Technologies, Lexington, KY), intramuscular; or group (3) 0.5-mg BioRelease Histrelin, intramuscular.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In broodmares, ovulatory responses appeared to improve as the season progressed with both histrelin and hCG.

    In plain wordsIn mares, ovulatory responses appeared to improve as the season progressed with both histrelin and hCG.

    Peptide
    Histrelin
    Outcome
    IncreaseOvulatory response over the breeding season
    Study

    horsen: not reported in source

    Broodmares in estrus
    Comparator
    Earlier in the breeding season
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Ovulatory responses appeared to improve for both products as the season progressed, yet no differences were detected between response rates to histrelin or hCG for any month (P ≥ .50).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.